In Enterobacterales bacteremia, antipseudomonal β-lactam de-escalation was noninferior to continuation for clinical cure at 3 to 5 d.

Konstantinos Ouranos, Eleftherios Mylonakis

Research output: Contribution to journalArticlepeer-review

Abstract

López-Cortés LE, Delgado-Valverde M, Moreno-Mellado E, et al; SIMPLIFY study group. Efficacy and safety of a structured de-escalation from antipseudomonal β-lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): an open-label, multicentre, randomised trial. Lancet Infect Dis. 2024;24:375-385. 38215770.

Original languageEnglish (US)
Pages (from-to)JC52
JournalAnnals of Internal Medicine
Volume177
Issue number5
DOIs
StatePublished - May 1 2024

Keywords

  • beta-Lactams/therapeutic use
  • Drug Administration Schedule
  • Enterobacteriaceae Infections/drug therapy
  • Humans
  • Enterobacteriaceae/drug effects
  • Middle Aged
  • Male
  • Female
  • Bacteremia/drug therapy
  • Aged
  • Anti-Bacterial Agents/therapeutic use

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint

Dive into the research topics of 'In Enterobacterales bacteremia, antipseudomonal β-lactam de-escalation was noninferior to continuation for clinical cure at 3 to 5 d.'. Together they form a unique fingerprint.

Cite this